BRISTOL, Tenn., Nov. 8 /PRNewswire-FirstCall/ -- King Pharmaceuticals,
Inc. (NYSE: KG) reported that the results from the Prevention of Events with
Angiotensin-Converting-Enzyme Inhibitors (PEACE) trial were released yesterday
at the annual meeting of the American Heart Association (AHA). PEACE -- a
large-scale, randomized, placebo-controlled clinical trial -- evaluated
whether patients with stable coronary artery disease and normal or slightly
reduced left ventricular function derive therapeutic benefit from the addition
of the angiotensin-converting-enzyme (ACE) inhibitor trandolapril 4 mg to
modern conventional therapy. Data from the PEACE trial failed to demonstrate
that trandolapril confers such a benefit.
Conversely, data from the Heart Outcomes Prevention Evaluation (HOPE)
trial, released five years ago at the AHA annual meeting, successfully
demonstrated that King's ACE inhibitor, Altace(R) (ramipril) 10 mg,
significantly reduced the risk of heart attack, stroke, and cardiovascular
death by an average of 22 percent in patients age 55 and older at high risk
for developing a cardiovascular event. Based on data from the large-scale
(9,541 patients), randomized, placebo-controlled HOPE trial, Altace(R) is the
only ACE inhibitor indicated for the reduction in risk of myocardial
infarction, stroke, and death from cardiovascular causes in patients age 55
and older who are at high risk of developing a cardiovascular event due to a
history of coronary artery disease, stroke, peripheral vascular disease, or
diabetes accompanied by at least one other cardiovascular risk factor.
Charles L. Pamplin, III, M.D., Vice President, Medical Affairs of King
Pharmaceuticals, commented, "The results from the PEACE trial allow for the
possibility that there is no class effect among ACE inhibitors."
About Altace(R)
Altace(R) is indicated in patients 55 years or older at high risk of
developing a major cardiovascular event, either because of a history of
coronary artery disease, stroke, or peripheral vascular disease or because of
diabetes that is accompanied by at least one other cardiovascular risk factor
(hypertension, elevated total cholesterol levels, low HDL levels, cigarette
smoking, or documented microalbuminuria), to reduce the risk of stroke,
myocardial infarction, or death from cardiovascular causes. Altace(R) can be
used in addition to other needed treatments (such as antihypertensive,
antiplatelet, or lipid-lowering therapies).
Prescription Altace(R) is not for everyone. Altace(R) may cause swelling
of the mouth, tongue, or throat, which could cause extremely serious risk and
require immediate medical care. Altace(R) may lower blood sugar among
patients taking medicine for diabetes. Patients should contact their doctor
if they have symptoms of low blood sugar such as sweating or shakiness.
Common side effects include persistent dry cough, dizziness, and
light-headedness due to low blood pressure. Altace(R) should not be taken
during pregnancy, as death or injury to the unborn child may result, or if a
person has experienced serious side effects related to previous ACE
inhibitors.
About King Pharmaceuticals
King, headquartered in Bristol, Tennessee, is a vertically integrated
branded pharmaceutical company. King, an S&P 500 Index company, seeks to
capitalize on opportunities in the pharmaceutical industry through the
development, including through in-licensing arrangements and acquisitions, of
novel branded prescription pharmaceutical products in attractive markets and
the strategic acquisition of branded products that can benefit from focused
promotion and marketing and product life-cycle management.
SOURCE King Pharmaceuticals, Inc.
 back to top
Related links:
http://www.kingpharm.com
CONTACT:
James E. Green, Executive Vice President,
Corporate Affairs of King Pharmaceuticals, Inc., +1-423-989-8125
|
